We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

69 hedge funds and large institutions have $93.6M invested in Protagonist Therapeutics in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 22

9.14% more ownership

Funds ownership: 56.56% → 65.7% (+9.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 17

1% less funds holding

Funds holding: 70 → 69 (-1)

9% less capital invested

Capital invested by funds: $103M → $93.6M (-$8.9M)

Holders
69
Holders Change
-1
Holders Change %
-1.43%
% of All Funds
1.58%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
27
Reduced
22
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
GPP
Great Point Partners
Connecticut
+$11.3M
2
BI
BVF Inc
California
+$7.77M
3
Renaissance Technologies
Renaissance Technologies
New York
+$3.27M
4
Deutsche Bank
Deutsche Bank
Germany
+$2.14M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.75M

Top Sellers

1
EC
EcoR1 Capital
California
-$9.31M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.84M
3
BlackRock
BlackRock
New York
-$3.33M
4
PI
Pharmstandard International
Luxembourg
-$1.78M
5
State Street
State Street
Massachusetts
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Arrowstreet Capital
26
Arrowstreet Capital
Massachusetts
$560K +$640K +83,341 New
Goldman Sachs
27
Goldman Sachs
New York
$557K +$398K +51,795 +167%
ARTA
28
A.R.T. Advisors
New York
$526K +$602K +78,356 New
Invesco
29
Invesco
Georgia
$490K +$128K +16,656 +30%
JP Morgan Chase
30
JP Morgan Chase
New York
$461K +$509K +66,296 +2,889%
BCM
31
BlueCrest Capital Management
Jersey
$452K +$516K +67,279 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$426K +$102K +13,303 +27%
SAM
33
Senzar Asset Management
New York
$412K -$880K -114,686 -65%
PP
34
Paloma Partners
Connecticut
$373K +$426K +55,499 New
ECM
35
Element Capital Management
New York
$368K +$264K +34,371 +169%
AG
36
Algert Global
California
$349K +$398K +51,907 New
BCM
37
Bridgeway Capital Management
Texas
$340K +$89.1K +11,600 +30%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$337K +$386K +50,261 New
Squarepoint
39
Squarepoint
New York
$326K +$245K +31,936 +193%
Morgan Stanley
40
Morgan Stanley
New York
$308K +$134K +17,503 +62%
UBS Group
41
UBS Group
Switzerland
$276K +$315K +41,001 New
Balyasny Asset Management
42
Balyasny Asset Management
Illinois
$265K +$212K +27,616 +233%
FIM
43
Freedom Investment Management
Connecticut
$236K +$270K +35,133 New
LP
44
LMR Partners
United Kingdom
$210K +$240K +31,228 New
Northern Trust
45
Northern Trust
Illinois
$202K -$745K -97,016 -76%
FSA
46
Franklin Street Advisors
North Carolina
$183K -$149K -19,400 -42%
Barclays
47
Barclays
United Kingdom
$164K +$97.1K +12,650 +107%
PPA
48
Parametric Portfolio Associates
Washington
$156K +$178K +23,157 New
Walleye Trading
49
Walleye Trading
New York
$150K +$172K +22,365 New
Bank of America
50
Bank of America
North Carolina
$143K +$156K +20,319 +2,263%
1
2
3 4

PTGX Hedge Fund Activity: Q2 2018 in Review

69 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2018, worth a combined $93.6M — down 8.7% from $103M a quarter earlier.

Fund positioning in PTGX was balanced in Q2 2018: 17 funds opened new positions, 17 closed out, 27 added to existing stakes and 22 trimmed.

The largest buyer was Great Point Partners, opening a new position worth an estimated $11.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $9.31M sold.

  • 69 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2018, down from 70 in Q1 2018.
  • Funds reported $93.6M of Protagonist Therapeutics stock for Q2 2018, down 8.7% quarter-over-quarter.
  • 17 funds opened new Protagonist Therapeutics positions in Q2 2018 and 17 closed out, a net change of 0 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2018 was Great Point Partners, an estimated $11.3M added.
  • The largest Protagonist Therapeutics seller in Q2 2018 was EcoR1 Capital, an estimated $9.31M sold.

Based on aggregated 13F filings for Q2 2018.